Patient preferences for non-small-cell lung cancer treatment: A qualitative study - Rosanne Janssens
In this presentation, Rosanne Janssens (KU Leuven) shares the findings from the qualitative study that was part of the PREFER case study on lung cancer. The recording was made 13 January 2022, and the presentation was part of the PREFER webinar on patient preferences for non-small-cell lung cancer treatment options.
Watch the full webinar: https://youtu.be/1T9bpr3B06A
For more information about the project visit https://www.imi-prefer.eu/
The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
This video and its contents reflect the PREFER project's view and not the view of IMI, the European Union or EFPIA.
-
Category
No comments found